CN101961380A - Chinese compound preparation for treating coronary heart disease and preparation method thereof - Google Patents
Chinese compound preparation for treating coronary heart disease and preparation method thereof Download PDFInfo
- Publication number
- CN101961380A CN101961380A CN 200910159917 CN200910159917A CN101961380A CN 101961380 A CN101961380 A CN 101961380A CN 200910159917 CN200910159917 CN 200910159917 CN 200910159917 A CN200910159917 A CN 200910159917A CN 101961380 A CN101961380 A CN 101961380A
- Authority
- CN
- China
- Prior art keywords
- preparation
- ethanol
- relative density
- chinese medicinal
- clear paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a Chinese compound preparation for treating a coronary heart disease and a preparation method thereof. The preparation of the Chinese compound preparation for treating the coronary heart disease comprises the following steps of: (1) extracting root of red-rooted salvia by using ethanol, filtering the extracting solution and concentrating the filtrate to be clear plaster with the relative density of 1.01 at the temperature of between 55 and 60 DEG C; (2) decocting dregs of the root of red-rooted salvia with water, filtering, and concentrating the filtrate to be clear plaster with the relative density of 1.15 to 1.17 at the temperature of 60 DEG C; (3) extracting pseudo-ginseng by using aqueous solution of ethanol in a volume ratio of ethanol to water of 65 percent, filtering the extracting solution and concentrating the filtrate to be clear plaster with the relative density of 1.05 to 1.08; and (4) mixing the three kinds of clear plaster and borneol, wherein the weight ratio of the root of red-rooted salvia to the pseudo-ginseng to the borneol is 650-700:200-230:8-15. Clinical test show that: the Chinese compound preparation prepared by the preparation method has the extract curative effect of treating the coronary heart disease and angina pectoris (a qi stagnation and blood stasis disease) and no toxic or side effect caused by the medicament in the clinical tests, is safe and effective for treating the coronary heart disease and angina pectoris (the qi stagnation and blood stasis disease), and has better curative effect than that of compound salvia tablets.
Description
Technical field
The present invention relates to a kind of compound Chinese medicinal preparation for the treatment of coronary heart disease and preparation method thereof, be specifically related to compound Chinese medicinal preparation of a kind of treatment coronary heart disease that comprises Radix Salviae Miltiorrhizae and preparation method thereof.
Background technology
(coronary artery heart disease CHD) is called for short coronary heart disease to coronary heart disease, is meant the myocardial dysfunction and/or the organic disease that cause because of coronary stricture, blood supply insufficiency, so claim ischemic cardiomyopathy (IHD) again.At present, because the change of people life style, overnutrition, physical exertion is fewer and feweri, and it is overweight to have caused health to be got fat easily, and it is numerous to add smoking population, makes the paathogenic factor of coronary heart disease significantly increase.Coronary heart disease has become one of modal disease in the chronic cardiovascular disease.The clinical symptoms of coronary heart disease comprises angina pectoris, myocardial infarction, arrhythmia, heart failure and sudden death etc., and its threat to human life and health is serious day by day.
Chinese invention patent application 200410072942.7 discloses a kind of preparation method of FUFANG DANSHEN PIAN, and it is that crude drug is made with Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum, and the processing step of its preparation is: with Radix Salviae Miltiorrhizae, panax mixed or make water extract or alcohol extract separately; Described extracting solution is carried out predefecation to be handled; Further described extracting solution is carried out hyperfiltration treatment; Ultrafiltrate is concentrated, add Borneolum Syntheticum, make tablet according to a conventional method.This FUFANG DANSHEN PIAN has the effect of blood circulation promoting and blood stasis dispelling, regulating QI to relieve pain, is used for feeling oppressed in the heart, anginal treatment.But there is following problem in above-mentioned preparation method: (1) leaching process carries out at normal temperatures, causes effective ingredient such as Radix Notoginseng total arasaponins, danshensu and polysaccharose substance fully not extracted; (2) adopt hyperfiltration treatment to cause active substance such as macromole saccharide and Panax Notoginseng saponin R g1 to run off in a large number.Through experiment confirm, molecular weight can't pass through ultrafilter membrane at the effective ingredient more than 5000, and with total loss, and the medical value of this part material is very high, is the important activity composition that improves patient's immunity, blood vessel dilating.
Summary of the invention
Therefore, the object of the present invention is to provide a kind of compound Chinese medicinal preparation for the treatment of coronary heart disease and preparation method thereof, anginal compound Chinese medicinal preparation that particularly a kind of effective treatment coronary heart disease causes and preparation method thereof, the active constituent content of this compound Chinese medicinal preparation is higher, thereby can more effectively be applied to the treatment of coronary heart disease.
Technical scheme of the present invention is as follows:
A kind of preparation method for the treatment of the compound Chinese medicinal preparation of coronary heart disease, this preparation method may further comprise the steps:
(1) adopts the ethanol extraction Radix Salviae Miltiorrhizae, filter extracting solution, and under 55～60 ℃ be 1.01 clear paste filtrate simmer down to relative density;
(2) Radix Salviae Miltiorrhizae decoction dregs decocts with water after-filtration, under 60 ℃ is 1.15～1.17 clear paste with filtrate simmer down to relative density;
(3) adopting 65% (volume/volume) ethanol water to extract Radix Notoginseng, filter extracting solution, under 60 ℃ is 1.05～1.08 clear paste with filtrate simmer down to relative density;
(4) above-mentioned 3 kinds of clear paste are mixed with Borneolum Syntheticum;
Wherein, Radix Salviae Miltiorrhizae, Radix Notoginseng are 650～700: 200～230 with the ratio of the parts by weight of Borneolum Syntheticum: 8～15.Preferably, Radix Salviae Miltiorrhizae, Radix Notoginseng are 675: 211.5: 12 with the ratio of the parts by weight of Borneolum Syntheticum.
In above-mentioned preparation method, preferably, the reduced-pressure backflow that is extracted as in the step (1) extracted 1.5 hours; Radix Salviae Miltiorrhizae decoction dregs in the step (2) decocts with water three times, each 1.5 hours; Radix Notoginseng in the step (3) is with 65% (volume/volume) ethanol water reflux, extract, three times, 1.5 hours for the first time, second and third time each 1 hour.
In a specific embodiments of above-mentioned preparation method, it may further comprise the steps:
(1) Radix Salviae Miltiorrhizae powder is broken into coarse granule, adds the ethanol reduced-pressure backflow and extracted 1.5 hours, filter, decompression filtrate recycling ethanol is concentrated into relative density under 55～60 ℃ and is 1.01 clear paste; Medicinal residues decoct with water three times, and each 1.5 hours, filter, it is 1.15～1.17 clear paste that 60 ℃ of following filtrate is concentrated into relative density;
(2) Radix Notoginseng powder is broken into coarse granule, adds 65% (volume/volume) ethanol water reflux, extract, three times, and 1.5 hours for the first time, second and third time each 1 hour filtered, and 60 ℃ are reclaimed the ethanol in the filtrate down and are concentrated into relative density is 1.05～1.08 clear paste;
(3) get mannitol and silicon dioxide is an amount of, mixing sprays into above-mentioned 3 kinds of clear paste successively, and drying is made granule, adds Borneolum Syntheticum, is ground into fine powder, and mixing is packed enteric coated capsule into promptly.
The present invention also provides the compound Chinese medicinal preparation of above-mentioned preparation method preparation.This compound Chinese medicinal preparation can be preferably enteric coated capsule for tablet, capsule or granule.
Above-mentioned compound Chinese medicinal preparation can be treated the angina pectoris that coronary heart disease causes.
The present invention finds through lot of experiments, when extracting Radix Salviae Miltiorrhizae and Radix Notoginseng under normal temperature condition, no matter is that water is carried or alcohol extraction, 5 ℃ of the every raisings of temperature, and effective yield of Radix Notoginseng total arasaponins or danshensu all can increase by 3%.But when temperature surpasses 65 ℃ critical temperature, chemical reaction will take place in the Rg1 in the Radix Notoginseng total arasaponins.So 60 ℃ is more satisfactory extraction temperature.
The present invention adopt the double blinding dual analog, at random the contrast, the multiple center trial method for designing, with FUFANG DANSHEN PIAN medicine in contrast, O﹠A the effectiveness and the safety of compound Chinese medicinal preparation treatment angina pectoris of the present invention (Chinese medical discrimination is a qi depression to blood stasis disease).Aspect curative effect, relatively, its difference has statistical significance through between the comprehensive therapeutic effect group, and test group is better than matched group.The onset time that pain frequency, durante dolors change after the medication was no more than for 1 week, was time-effect relationship in 4 weeks, and test group is better than matched group.The use amount of test group nitroglycerin obviously reduces after the medication.Aspect safety, before and after the test group treatment 114 routine patients blood, urine, just routine, liver function (AST) and renal function (BUN), Electrocardioscopy have been carried out, before having analyzed and treated, the doctor who is responsible for clinical trial transfers unusual person to after the normal therapeutic, and the situation that does not increase the weight of the person before the treatment after the cure of abnormalities unusually, judge with trial drug irrelevant.Results of pharmacodynamic test shows: compound Chinese medicinal preparation of the present invention can make the ischemic electrocardiogram of the dog of coronary artery ligation improve, infarct size dwindles, obviously reduce myocardial oxygen consumption, the level of serum aspartate amino transferase (AST), lactic acid dehydrogenase (LDH), creatine kinase (CK) reduces; Also can improve the myocardial ischemia of coronary artery ligation rat.Adenosine diphosphate (ADP) (ADP), arachidonic acid (AA) and collagen-induced rat platelet aggregation there is certain inhibitory action.Can prolong the experimental artery thrombosis time due to the electricity irritation rat carotid artery, reduce the whole blood viscosity of syndrome of blood stasis rat model.
In sum, clinical trial shows: compound Chinese medicinal preparation treatment angina pectoris (syndrome of qi stagnation and blood stasis) determined curative effect of the present invention, do not see the toxic and side effects of drug-induced in the clinical trial, be the safe and effective medicine of treatment angina pectoris (syndrome of qi stagnation and blood stasis), and curative effect is better than FUFANG DANSHEN PIAN.In addition, compound Salviae Miltiorrhizae enteric coated capsule of the present invention can also be eliminated the stimulation of medicines such as Borneolum Syntheticum, Radix Notoginseng to gastric mucosa.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is further described in detail, the embodiment that provides is only in order to illustrate the present invention, rather than in order to limit the scope of the invention.
Embodiment 1The preparation of compound Salviae Miltiorrhizae enteric coated capsule
Prescription: Radix Salviae Miltiorrhizae 675g Radix Notoginseng 211.5g Borneolum Syntheticum 12g
Method for making: above three flavors, Radix Salviae Miltiorrhizae powder is broken into coarse granule, adds the ethanol reduced-pressure backflow and extracts 1.5 hours, filter, decompression filtrate recycling ethanol, being concentrated into relative density is the clear paste of 1.01 (55～60 ℃); Medicinal residues decoct with water three times, and each 1.5 hours, filter, filtrate is concentrated into the clear paste that relative density is 1.15～1.17 (60 ℃); Radix Notoginseng powder is broken into coarse granule, adds 65% (volume/volume) ethanol water reflux, extract, three times, and 1.5 hours for the first time, second and third time each 1 hour filtered, and filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.05～1.08 (60 ℃).Get mannitol, silicon dioxide is an amount of, mixing sprays into above-mentioned 3 kinds of clear paste successively, drying is made granule, adds Borneolum Syntheticum, is ground into fine powder, mixing, the enteric coated capsule of packing into is made 1000, promptly.
Character: this product is an enteric coated capsule; Content is that lark is to xanchromatic powder; Gas perfume (or spice), mildly bitter flavor.
Test example 1The clinical test of pesticide effectiveness of compound Salviae Miltiorrhizae enteric coated capsule
1. EXPERIMENTAL DESIGN: adopt multicenter, at random, the test method of double blinding dual analog, carry out parallel control with FUFANG DANSHEN PIAN as positive drug, estimate the clinical drug effect of compound Salviae Miltiorrhizae enteric coated capsule treatment angina pectoris (syndrome of qi stagnation and blood stasis).
2. test crowd: select the age 45～70 years old men and women patient, the case that all meets the dialectical standard of angina pectoris (syndrome of qi stagnation and blood stasis) diagnosis is the object of observation.
Treatment and medication: after the experimenter is entered test group or matched group by random assortment, accept the Drug therapy in 4 weeks.Each 2 of oral compound Salviae Miltiorrhizae enteric coated capsule of the present invention is organized in treatment, and every day 3 times, taking medicine before meal is used; Each 3 of matched group oral administered compound Radix Salviae Miltiorrhizae Tabellae, every day 3 times.
3. evaluation index:
(1) efficiency assessment index: respectively in the risk factor of 1 patient's of the 0th, 1,2,3,4 whens week observational record of treatment stage angina pectoris attacks, the size of physical exertion, degree, the number of times of pain, degree, persistent period, consumption of nitroglycerin preparation etc. and relevant sign, the variation of traditional Chinese medical science syndrome of qi stagnation and blood stasis syndrome, and respectively check electrocardiogram 1 time before the test, when test the 2nd week back and off-test, before and after medication, respectively measure 1 blood fat and hemorheology simultaneously and learn index.
(2) safety evaluation index: treat forward and backward mensuration and the Electrocardioscopy of carrying out general vital sign (body temperature, breathing, pulse, blood pressure), blood, urine, stool routine (+occult blood) regulating liver-QI (ALT, AST), renal function (BUN, Cr); In whole medication process, observe the untoward reaction, particularly digestive tract reaction that may occur.
4. statistical analysis: all statistical test all adopt two-sided test, think that the P value is less than or equal at 0.05 o'clock, and the difference of being checked has statistical significance.
5. comprehensive therapeutic effect
The comprehensive therapeutic effect that the treatment back is two groups is as shown in table 1:
Table 1 liang group comprehensive therapeutic effect relatively
Annotate: produce effects: cardinal symptoms such as angina pectoris disappear or reach the produce effects standard, and electrocardiogram returns to normal ECG or reaches roughly normal (being electrocardiogram normal range); Effectively: cardinal symptoms such as angina pectoris alleviate or reach effective standard, and electrocardiogram improves effective standard that reaches; Invalid: cardinal symptoms such as angina pectoris do not have improvement, and electrocardiogram is preceding identical with treatment substantially; Increase the weight of: cardinal symptom such as angina pectoris and electrocardiogram increase the weight of before the test.When comprehensive therapeutic effect is judged,, should be comprehensive therapeutic effect with the low result of curative effect if when cardinal symptom curative effect such as angina pectoris and ECG curative effect are inconsistent.
Two groups of curative effects are through rank test, Hc=4.2705, and df=1, p=0.0388, p＜0.05, difference has statistical significance.According to binomial distribution as can be known: the obvious effective rate of compound Salviae Miltiorrhizae enteric coated capsule treatment angina pectoris (syndrome of qi stagnation and blood stasis) patient comprehensive therapeutic effect is 95% confidence interval: 8.064%～22.066%; Total effective rate is 95% confidence interval: 53.690%～72.642%; The obvious effective rate of contrast recurrence due to taking drug side Radix Salviae Miltiorrhizae Tabellae treatment angina pectoris (syndrome of qi stagnation and blood stasis) patient comprehensive therapeutic effect is 95% confidence interval: 6.229%～19.649%; Total effective rate is 95% confidence interval: 38.039%～58.156%.The comprehensive therapeutic effect that compound Salviae Miltiorrhizae enteric coated capsule treatment angina pectoris (syndrome of qi stagnation and blood stasis) patient is described is better than FUFANG DANSHEN PIAN.
6. seizure frequency
The angina pectoris attacks frequency shift is as shown in table 2 after the medication.
Two groups of patient's angina pectoris attacks frequencies (inferior/week) change after table 2 medication
*Annotate: frequency after frequency-medication before difference=medication
The treatment group: the forward and backward pain frequency change of medication is through the variance test of homogeneity, card side=50.4341, df=4, p=0.0000, P＜0.05, heterogeneity of variance.Through Kruskal Wallis check, KW statistic=117.7708, the test of significance that approximate card side distributes, p=0.0000, difference has statistical significance.Comparative result is as shown in table 3 in twos:
Table 3 treatment group pain frequency dynamic changes
Illustrate that treatment group medication 1 week back pain frequency significantly reduces (P＜0.05), 21 week of back pain frequency ratios week the back, 3 week the back than 2 week the back and 4 week the back than 3 weeks after the reduction of pain frequencies all reached significant level (P equal＜0.05).
Matched group: the forward and backward pain frequency change of medication is through the variance test of homogeneity, card side=37.8554, df=4, p=0.0000, P＜0.05, heterogeneity of variance.Through Kruskal Wallis check, KW statistic=71.28076, the test of significance that approximate card side distributes, p=0.0000, difference has statistical significance.Comparative result is as shown in table 4 in twos:
Table 4 matched group pain frequency dynamic changes
The pain frequency significantly reduced (P＜0.05) after 1 week of matched group medication was described, though the back pain frequency continuation of 2 weeks reduces, but compare with 1 all backs, the pain frequency reduces and not to reach significant level (P＞0.05), however 3 week the back than 2 week the back and 4 week the back than 3 weeks after the reduction of pain frequencies all reached significant level (P equal＜0.05).
Compare between two groups: change relatively before and after two groups of pain frequencies treatments, check through t, two handle variances does not wait (p=0.0434), and its average significance test of difference is t=2.2201 as a result, p=0.0275, and P＜0.05, difference has statistical significance.Difference illustrates that greater than matched group the treatment group is better than matched group to the curative effect of improving of angina pectoris attacks frequency before and after the medication of combined treatment group.
7. durante dolors:
The change of durante dolors is as shown in table 5 after the medication.
Pain average duration after table 5 medication (minute) variation
*Back pain average duration 4 week of pain average duration-medication before difference=medication
The treatment group: before the medication with back pain average duration 1,2,3,4 week of medication through the variance test of homogeneity, card side=24.4335, df=4, p=0.00007, P＜0.05, heterogeneity of variance.Through the KruskalWallis check, KW statistic=120.45712, the test of significance that approximate card side distributes, p=0.0000, difference has statistical significance.Comparative result is as shown in table 6 in twos:
The average duration dynamic change of table 6 treatment group pain
Illustrate that back pain average duration in treatment group medication 1 week significantly shortens (P＜0.05), 2 back pain average durations in week than 1 week the back, 3 week the back than 2 week the back and 4 week the back than 3 all after the shortening of pain average duration all reached significant level (P equal＜0.01).
Matched group: before the medication with back pain average duration 1,2,3,4 week of medication through the variance test of homogeneity, card side=51.8036, df=4, p=0.00000, P＜0.05, heterogeneity of variance.Through the KruskalWallis check, KW statistic=85.07925, the test of significance that approximate card side distributes, p=0.0000, difference has statistical significance.Comparative result is as shown in table 7 in twos:
The average duration dynamic change of table 7 matched group pain
Illustrate that back pain average duration in matched group medication 1 week significantly shortens (P＜0.05), 2 back pain average durations in week than 1 week the back, 3 week the back than 2 week the back and 4 week the back than 3 all after the shortening of pain average duration all reached significant level (P equal＜0.05).
Compare between two groups: pain average duration differences relatively before and after two groups of medications, check through t, two handle homogeneity of variance (p=0.6476), its average significance test of difference is t=1.5220 as a result, p=0.1295, P＞0.05, the difference not statistically significant, illustrate two groups similar to the durante dolors curative effect.
8. nitroglycerin operating position
The variation of nitroglycerin operating position is shown in table 8, table 9 after the medication.
Table 8 liang group patient buccal nitroglycerin case load relatively
*Annotate: rate of descent=(not needing to use the case load that does not need to use nitroglycerin before the case load-treatment of nitroglycerin after the treatment)/need to use before treating case load * 100% of nitroglycerin
Before and after two groups of patient's medications buccal nitroglycerin cases relatively, through the four fold table analysis, P all＜0.05, difference has statistical significance.Two groups of treatment backs use the nitroglycerin situation relatively, through the four fold table analysis, and general card side=0.7172, df=1, p=0.3971, P＞0.05, difference not statistically significant.
The variation of table 9 liang group patient's forward and backward nitroglycerin using dosage of medication (mg/ time)
*Annotate: the case load that refers to use in the observation process pernitric acid glycerol
Treat forward and backward patient's nitroglycerin using dosage relatively for two groups, through paired t-test, P all＜0.05, difference has statistical significance, illustrates that the using dosages of two groups of treatment back nitroglycerin significantly reduce.Compare between two groups: nitroglycerin difference after two groups of medications (use reduction) compares, and through t check in groups, two handle heterogeneity of variances (p=0.0041), its average significance test of difference is t=1.2362 as a result, p=0.2190, P＞0.05, difference not statistically significant.
Consolidated statement 8 and table 9 illustrate that the operating position of nitroglycerin can both significantly reduce after two groups of medications, also promptly two groups all anginal pain degree is had clear improvement.Two groups to the angina pectoris pain degree to improve curative effect similar.
9. safety analysis
Safety indexes changes: before and after two groups of treatments to safety indexes variation after the testing result of safety index and the medication of trial drug group or increase the weight of situation unusually and analyze as shown in table 10.
The forward and backward safety indexes of table 10 medication changes
As shown in table 4, trial drug compound Salviae Miltiorrhizae enteric coated capsule has no adverse effects to angina pectoris (syndrome of qi stagnation and blood stasis) patient's safety indexes.
In addition, do not occur adverse events in the clinical trial process and describe, side effect of digestive tract does not take place.1 grade of safety evaluatio.
Claims (10)
1. preparation method for the treatment of the compound Chinese medicinal preparation of coronary heart disease, this preparation method may further comprise the steps:
(1) adopts the ethanol extraction Radix Salviae Miltiorrhizae, filter extracting solution, and under 55～60 ℃ be 1.01 clear paste filtrate simmer down to relative density;
(2) Radix Salviae Miltiorrhizae decoction dregs decocts with water after-filtration, under 60 ℃ is 1.15～1.17 clear paste with filtrate simmer down to relative density;
(3) adopting 65% (volume/volume) ethanol water to extract Radix Notoginseng, filter extracting solution, under 60 ℃ is 1.05～1.08 clear paste with filtrate simmer down to relative density;
(4) above-mentioned 3 kinds of clear paste are mixed with Borneolum Syntheticum;
Wherein, Radix Salviae Miltiorrhizae, Radix Notoginseng are 650～700: 200～230 with the ratio of the parts by weight of Borneolum Syntheticum: 8～15.
2. preparation method according to claim 1 is characterized in that, described Radix Salviae Miltiorrhizae, Radix Notoginseng are 675: 211.5: 12 with the ratio of the parts by weight of Borneolum Syntheticum.
3. preparation method according to claim 1 and 2 is characterized in that, the reduced-pressure backflow that is extracted as in the described step (1) extracted 1.5 hours.
4. according to each described preparation method in the claim 1 to 3, it is characterized in that the Radix Salviae Miltiorrhizae decoction dregs in the described step (2) decocts with water three times, each 1.5 hours.
5. according to each described preparation method in the claim 1 to 4, it is characterized in that the Radix Notoginseng in the described step (3) is with 65% (volume/volume) ethanol water reflux, extract, three times, 1.5 hours for the first time, second and third time each 1 hour.
6. according to each described preparation method in the claim 1 to 5, it is characterized in that described preparation method may further comprise the steps:
(1) Radix Salviae Miltiorrhizae powder is broken into coarse granule, adds the ethanol reduced-pressure backflow and extracted 1.5 hours, filter, decompression filtrate recycling ethanol is concentrated into relative density under 55～60 ℃ and is 1.01 clear paste; Medicinal residues decoct with water three times, and each 1.5 hours, filter, it is 1.15～1.17 clear paste that 60 ℃ of following filtrate is concentrated into relative density;
(2) Radix Notoginseng powder is broken into coarse granule, adds 65% (volume/volume) ethanol water reflux, extract, three times, and 1.5 hours for the first time, second and third time each 1 hour filtered, and 60 ℃ are reclaimed the ethanol in the filtrate down and are concentrated into relative density is 1.05～1.08 clear paste;
(3) get mannitol and silicon dioxide is an amount of, mixing sprays into above-mentioned 3 kinds of clear paste successively, and drying is made granule, adds Borneolum Syntheticum, is ground into fine powder, and mixing is packed enteric coated capsule into promptly.
7. according to the compound Chinese medicinal preparation of each described preparation method preparation in the claim 1 to 6.
8. compound Chinese medicinal preparation according to claim 7 is characterized in that, described compound Chinese medicinal preparation is tablet, capsule or granule.
9. according to claim 7 or 8 described compound Chinese medicinal preparation, it is characterized in that described compound Chinese medicinal preparation is an enteric coated capsule.
10. according to each described compound Chinese medicinal preparation in the claim 7 to 9, it is characterized in that the angina pectoris that described compound Chinese medicinal preparation treatment coronary heart disease causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910159917 CN101961380A (en) | 2009-07-23 | 2009-07-23 | Chinese compound preparation for treating coronary heart disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910159917 CN101961380A (en) | 2009-07-23 | 2009-07-23 | Chinese compound preparation for treating coronary heart disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101961380A true CN101961380A (en) | 2011-02-02 |
Family
ID=43514554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910159917 Pending CN101961380A (en) | 2009-07-23 | 2009-07-23 | Chinese compound preparation for treating coronary heart disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101961380A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102302548A (en) * | 2011-08-26 | 2012-01-04 | 太极集团重庆涪陵制药厂有限公司 | Preparation method for compound salvia tablets |
| CN102552395A (en) * | 2011-12-30 | 2012-07-11 | 郑州瑞龙制药股份有限公司 | Preparation method of compound red-rooted salvia root tablet |
| CN103656012A (en) * | 2013-12-16 | 2014-03-26 | 无锡济民可信山禾药业股份有限公司 | Formula of drug for treating coronary heart disease and angina pectoris and application of formula |
| CN110448594A (en) * | 2019-08-16 | 2019-11-15 | 金鸿药业股份有限公司 | A kind of preparation process and compound red sage root preparation of compound red sage root preparation |
-
2009
- 2009-07-23 CN CN 200910159917 patent/CN101961380A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102302548A (en) * | 2011-08-26 | 2012-01-04 | 太极集团重庆涪陵制药厂有限公司 | Preparation method for compound salvia tablets |
| CN102552395A (en) * | 2011-12-30 | 2012-07-11 | 郑州瑞龙制药股份有限公司 | Preparation method of compound red-rooted salvia root tablet |
| CN103656012A (en) * | 2013-12-16 | 2014-03-26 | 无锡济民可信山禾药业股份有限公司 | Formula of drug for treating coronary heart disease and angina pectoris and application of formula |
| CN110448594A (en) * | 2019-08-16 | 2019-11-15 | 金鸿药业股份有限公司 | A kind of preparation process and compound red sage root preparation of compound red sage root preparation |
| CN110448594B (en) * | 2019-08-16 | 2021-07-23 | 金鸿药业股份有限公司 | Preparation process of compound salvia miltiorrhiza preparation and compound salvia miltiorrhiza preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028900B (en) | Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof | |
| CN102614387A (en) | Traditional Chinese medicine for prevention and treatment of stroke and preparation method thereof | |
| CN102940801A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN101607074A (en) | A kind of drug regimen for the treatment of chronic gastritis and preparation method thereof | |
| CN101961380A (en) | Chinese compound preparation for treating coronary heart disease and preparation method thereof | |
| CN100333750C (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN101607031B (en) | Medicated wine for curing and preventing diabetes mellitus, preparation method and application method thereof | |
| CN101843843A (en) | Chinese medicament for treating diabetes | |
| CN102743646B (en) | Medicinal composition for inspecting and preventing diabetes | |
| CN101450189B (en) | Medicine for curing angiocardiopathy and cerebrovascular disease and its preparing method | |
| CN103908539A (en) | Traditional Chinese medicine composition for treating hypertension as well as preparation method and application of traditional Chinese medicine composition | |
| CN101254266B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN103550335B (en) | Traditional Chinese medicinal composition for improving liver function | |
| CN104324134B (en) | One kind improves microcirculatory Chinese medicine composition and preparation method thereof | |
| CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN101559139A (en) | Prescription of pure traditional Chinese medicine preparation for preventing and curing neurasthenia insomnia and preparation method thereof | |
| CN1850160A (en) | Qidantongmai Tablet, and its preparing process | |
| CN103920023A (en) | Traditional Chinese medicine for treating hypertension | |
| CN116370556B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, tonifying qi and soothing nerves and preparation method thereof | |
| CN101181342A (en) | Pharmaceutical combination with resisting liver cancer activity | |
| CN108743676B (en) | Application method of white peony root in preparation of medicine for treating hypertension | |
| CN101683459B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating sleep disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110202 |